Journal of Cancer Research and Clinical Oncology

, Volume 134, Issue 12, pp 1385–1396

Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study

  • Yoichi Arai
  • Hideyuki Akaza
  • Takashi Deguchi
  • Masato Fujisawa
  • Mikio Hayashi
  • Yoshihiko Hirao
  • Hiroshi Kanetake
  • Seiji Naito
  • Mikio Namiki
  • Masaaki Tachibana
  • Michiyuki Usami
  • Yasuo Ohashi
Original Paper

DOI: 10.1007/s00432-008-0409-z

Cite this article as:
Arai, Y., Akaza, H., Deguchi, T. et al. J Cancer Res Clin Oncol (2008) 134: 1385. doi:10.1007/s00432-008-0409-z

Abstract

Purpose

To assess quality of life (QOL) data from a double-blind Phase III study evaluating bicalutamide (Casodex™) 80 mg as part of maximum androgen blockade (MAB) in patients with previously untreated advanced prostate cancer.

Methods

Patients with untreated stage C/D prostate cancer were randomized to MAB with bicalutamide plus a luteinizing hormone-releasing hormone agonist (LHRHa) or LHRHa monotherapy. QOL was evaluated at baseline and at weeks 1, 5, and 24 using the Japanese version of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire.

Results

A total of 203 patients were assessed for QOL. The MAB group had more rapid and greater improvements in “emotional well-being” and “prostate cancer-specific issues” domain scores than the monotherapy group. Further analysis of “prostate cancer-specific issues” revealed that, compared with monotherapy, MAB provided a greater improvement in “micturition disorder”-related QOL. Complete improvement rates for items related to “pain and micturition disorder” were also higher with MAB. Item scores of “pain and micturition disorder” did not correlate strongly with prostate-specific antigen levels or tumor size. Fewer patients who had deterioration in their “pain and micturition disorder” item scores at week 1 in the MAB group than the monotherapy group.

Conclusions

Maximum androgen blockade with bicalutamide plus LHRHa did not reduce the overall QOL of patients with previously untreated advanced prostate cancer. MAB was superior to monotherapy in achieving early improvement of QOL related to micturition disorder and pain.

Keywords

Advanced prostate cancer Bicalutamide Luteinizing hormone releasing hormone agonist Maximum androgen blockade Quality of life 

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Yoichi Arai
    • 1
  • Hideyuki Akaza
    • 2
  • Takashi Deguchi
    • 3
  • Masato Fujisawa
    • 4
  • Mikio Hayashi
    • 5
  • Yoshihiko Hirao
    • 6
  • Hiroshi Kanetake
    • 7
  • Seiji Naito
    • 8
  • Mikio Namiki
    • 9
  • Masaaki Tachibana
    • 10
  • Michiyuki Usami
    • 11
  • Yasuo Ohashi
    • 12
  1. 1.Tohoku University School of MedicineMiyagiJapan
  2. 2.Institute of Clinical MedicineUniversity of TsukubaIbarakiJapan
  3. 3.Gifu University School of MedicineGifuJapan
  4. 4.Kobe University School of MedicineHyogoJapan
  5. 5.National Nagasaki Medical CenterNagasakiJapan
  6. 6.Nara Medical UniversityNaraJapan
  7. 7.Nagasaki University School of MedicineNagasakiJapan
  8. 8.Kyushu University Faculty of MedicineFukuokaJapan
  9. 9.Kanazawa University School of MedicineIshikawaJapan
  10. 10.Tokyo Medical UniversityTokyoJapan
  11. 11.Osaka Medical Center for Cancer and Cardiovascular DiseasesOsakaJapan
  12. 12.School of Health Sciences and NursingThe University of TokyoTokyoJapan

Personalised recommendations